Aprea Therapeutics (APRE)

• Market cap: $5.84M
• 1 day: -1.06%
• 5 days: -11.06%
• 1 month: -22.27%
• 3 months: -38.74%
• 6 months: -47.74%
• Year to date: -74.09%
• 1 year: -71.63%
• 5 years: -99.84%
• 10 years: -99.77%
• Sector: Healthcare
• Industry: Biotechnology

About: Aprea Therapeutics Inc is a clinical-stage biopharmaceutical company. The group is focused on precision oncology through synthetic lethality. Its pipeline products include ATRN-119, a clinical-stage small molecule ATR inhibitor in development for solid tumor indications. APR-1051, an oral, small-molecule WEE1 inhibitor, recently entered the clinic.

Employees: 8